ArticleBiochemistry and biophysics reports2026
Dose-dependent anxiolytic and antidepressant-like effects of chronic oxytocin in corticosterone-induced female mouse model of anxiety and depression.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxytocin (OXT) has therapeutic effects on psychiatric disorders, such as anxiety and depression, in both animals and humans; however, an increasing number of OXT treatment studies have reported conflicting results. Although the effects of OXT on emotion regulation vary depending on factors such as sex and dosage, the dose-dependent effects of chronic OXT administration remain unclear, particularly in women. In this study, we aimed to assess the dose-dependent effects of chronic OXT administration on emotional behavior in female mice with corticosterone (CORT)-induced anxiety and depression. A total of 58 female C57BL/6J mice received daily co-administration of OXT (0.1 or 1 mg/kg, intraperitoneal) and/or CORT (40 mg/kg, subcutaneous) for 4 weeks, and their anxiety- (open field and elevated plus maze tests) and depression-like behaviors (forced swimming and tail suspension tests) were evaluated. A 0.1 mg/kg dose of OXT blocked the CORT-induced increase in anxiety-like behavior (open field test) and depression-like behavior (forced swimming test), whereas the 1 mg/kg dose did not. Similarly, a dose-dependent effect of OXT was observed in the elevated plus maze and tail suspension tests. Furthermore, the 1 mg/kg dose of OXT significantly increased plasma OXT levels. These findings suggest that a certain level of OXT signaling activity is needed to exert anxiolytic and antidepressant-like effects, which may lead to a non-linear dose-dependent effect of OXT in a female mouse model of CORT-induced anxiety and depression. Targeting dose-dependent OXT signaling is a potential therapeutic strategy for women with psychiatric disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.